GenoMed In Talks with Cali, Colombia to Eliminate Most of Kidney Dialysis


David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938

ST. LOUIS—January 29, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that its CEO, David Moskowitz MD, is meeting with public health authorities in Cali, Colombia to discuss a program to prevent most kidney failure in Valle del Cauca, Cali’s department (“state”).

Valle del Cauca has 4 million residents. Most of them (2.8 million) live in its capital city, Cali. Many have diabetes.

GenoMed’s CEO, David Moskowitz MD, said, “Colombia, like all of the Americas, has a very high incidence of diabetes. Like the United States, Colombia has an epidemic of kidney failure. Unlike the US, Colombia is serious about preventing kidney failure. As the only company in the world with a cure for 90% of kidney failure, we’re delighted to be talking to public health authorities in Cali.”

Continued Dr. Moskowitz, “After years of getting nowhere marketing to the US and Europe, we’ve recently turned our attention to the developing world. We’re finding much more interest in our products.”

Dr. Moskowitz concluded by saying, “Ironically, the developing world may profit first from advances in personalized medicine. Less infrastructure—fewer hospitals and dialysis units–actually turns out to be an advantage. There’s much less financial resistance to clinical innovation. And the Internet allows us to deliver preventive molecular medicine inexpensively around the globe.”

About GenoMed

GenoMed published how to prevent 90% of kidney failure in 2002. It is now marketing its Next Generation Disease Management service globally to patients with diabetes or high blood pressure. Please contact GenoMed at or Safe”>

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.